Jounce Therapeutics Incorporated (NASDAQ:JNCE) Shorted Shares Increased By 1.98%

December 30, 2017 - By Kurt Siggers

 Jounce Therapeutics Incorporated (NASDAQ:JNCE) Shorted Shares Increased By 1.98%

The stock of Jounce Therapeutics Incorporated (NASDAQ:JNCE) registered an increase of 1.98% in short interest. JNCE’s total short interest was 3.34M shares in December as published by FINRA. Its up 1.98% from 3.27M shares, reported previously. With 140,500 shares average volume, it will take short sellers 24 days to cover their JNCE’s short positions.

The stock decreased 2.30% or $0.3 during the last trading session, reaching $12.75. About 89,853 shares traded. Jounce Therapeutics, Inc. (NASDAQ:JNCE) has 0.00% since December 30, 2016 and is . It has underperformed by 16.70% the S&P500.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. The company has market cap of $411.13 million. The Company’s lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. It currently has negative earnings. The firm is also developing JTX-4014, an anti-PD-1 antibody.

More notable recent Jounce Therapeutics, Inc. (NASDAQ:JNCE) news were published by: Globenewswire.com which released: “Jounce Therapeutics to Present at Cowen and Company 37th Annual Health Care …” on February 28, 2017, also Bizjournals.com with their article: “​Cambridge’s Jounce raises hopes as first Mass. biotech of 2017 to go public” published on January 27, 2017, Globenewswire.com published: “Jounce Therapeutics Announces Pricing of Initial Public Offering” on January 27, 2017. More interesting news about Jounce Therapeutics, Inc. (NASDAQ:JNCE) were released by: Seekingalpha.com and their article: “Jounce Therapeutics’ (JNCE) CEO Richard Murray on Q2 2017 Results – Earnings …” published on August 13, 2017 as well as Seekingalpha.com‘s news article titled: “Jounce Therapeutics’ (JNCE) CEO Richard Murray Presents at Stifel Nicolaus …” with publication date: November 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.